Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
June 25 (Reuters) - Gilead Sciences (GILD.O), opens new tab has entered into an option and license deal with Kymera Therapeutics (KYMR.O), opens new tab to support the development and sales of a class of cancer drugs, the companies said on Wednesday.
As part of the deal, Gilead would pay as much as $750 million, including up to $85 million upfront, in exchange for an option to gain global rights to develop, manufacture and sell Kymera's drug candidates that belong to a class called molecular glue degraders.
Kymera is also eligible to receive tiered royalties on net sales of the drugs under the deal.
Compared to traditional cancer drugs that inhibit the action of an associated protein, Kymera's drugs are designed to selectively eliminate proteins called CDK2, or cyclin-dependent kinase 2.
"This mechanism aligns within our oncology scientific framework where we evaluate therapeutic agents that selectively target and kill cancer cells with minimal impact on healthy tissue," said Flavius Martin, executive vice president of research at Gilead.
Kymera said it would lead all research activities for the drugs currently tested in preclinical studies and advance it as a potential treatment for breast cancer and other solid tumors.
The deal with Kymera is expected to reduce Gilead's 2025 profit per share by about two to three cents, the companies said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
17 minutes ago
- The Guardian
Member of RFK Jr's new vaccine panel withdraws over conflict of interest
A member of the health secretary Robert F Kennedy Jr's newly overhauled federal vaccine advisory panel withdrew after a conflict of interest review, a spokesperson has told the Guardian. Dr Michael Ross, who was involved in multiple private healthcare companies, withdrew after review of his financial holdings. Kennedy unilaterally fired all 17 members of the Centers for Disease Control and Prevention's (CDC) advisory committee on immunization practices (ACIP) in June, arguing they had too many conflicts of interest. Ross was among eight of Kennedy's ideological allies appointed to the committee, after the secretary argued the old members of the committee were subject to too many conflicts of interest. 'Yesterday, Dr Michael Ross decided to withdraw from serving on ACIP during the financial holdings review,' a spokesperson for the Department of Health and Human Services (HHS) said. 'The sacrifice to serve on ACIP varies from member to member, and we appreciate Dr Ross's willingness to go through this rigorous process.' The spokesperson made the comments after Guardian inquiries about conflict of interest disclosures for new members of ACIP. Although the Trump administration and Kennedy developed a conflict of interest tracker specifically for ACIP members, Kennedy's appointees have not been added. The HHS spokesperson did not respond to Guardian inquiries about when and where new, written conflict of interest disclosures would be published. Instead, the spokesperson said the department has, 'comprehensively reviewed all newly appointed ACIP members for conflicts of interests in accordance with federal law, regulations and departmental polices', and that the members were provided 'ethics training prior to discharging their duties'. The new members of the committee were asked to disclose conflicts of interest before the meeting began on Wednesday. The committee chair Dr Martin Kulldorff and committee member Dr Robert Malone omitted widely reported work in vaccine litigation, and nurse Vicky Pebsworth said she was 'asked to read' a statement disclosed ownership of a healthcare stock but said it was below the government ethics office threshold for reporting. Ethics review of the new members was also the subject of Senate testimony on Wednesday. Under questioning by the Democratic senator Patty Murray of Washington, the Trump nominee to head the CDC, Dr Susan Monarez, said she was 'not familiar whether or not the members that are participating in the meeting this week have or have not gone through the ethics review necessary to allow them to participate in those meetings'. 'If it is known that they have not gone through the ethics process and they issue recommendations, would you accept them as valid?' asked Murray. 'If they have not gone through an ethics approval process, they shouldn't be participating in the meetings,' said Monarez.
Sky News
33 minutes ago
- Sky News
Trump considers 'three or four' successors to 'stupid' Powell
Donald Trump has revived his criticism of the head of the US central bank, describing Jay Powell as "terrible" and "stupid", adding there were up to four candidates to succeed him. The president, who threatened to fire Mr Powell earlier this year before U-turning on that course early this month, has consistently demanded the Federal Reserve cut interest rates to help bolster economic growth. But the central bank has held off since Trump 2.0 began, citing threats to the pace of price growth from his on-off trade war. By raising tariffs on imports in a bid to boost US jobs and make US-produced goods more competitive, Mr Powell believes the spectre of inflation is looming over the world's largest economy. But the official inflation figures are yet to show any marked increase from rising import costs. "I know within three or four people who I'm going to pick," Mr Trump said in remarks to reporters while on his visit to Europe for the NATO summit at The Hague. He said Mr Powell was "an average-minded person" with a "low IQ for what he does." "I think he's a very stupid person, actually," he added. US media suggest the contenders to succeed Mr Powell include former Fed governor Kevin Warsh, National Economic Council head Kevin Hassett, current Fed governor Christopher Waller and Treasury Secretary Scott Bessent. The Fed chair is not due to leave his position until May next year. The Federal Reserve, like the Bank of England in the UK, is independent of government. Mr Trump is desperate to grow the economy after a sharp slowdown in the first quarter of the year was blamed on the threat of his trade war and early salvoes. Analysts see Mr Trump's on-off criticism of Mr Powell as an attempt to influence monetary policy through the back door. The prospects of a battle to remove him has previously rattled financial markets. For his part Mr Powell told a Congressional hearing on policy on Tuesday that higher tariffs from the trade war could push up inflation this summer - a time when the Fed has already indicated it could move to cut its target range for interest rates.
Reuters
39 minutes ago
- Reuters
Introducing Loio: Lawrina Rebrands With Powerful Document Creation Tools
NEW YORK, NY, June 25, 2025 (EZ Newswire) -- Lawrina, a trusted legal resource, announces an expanded mission and a new name: Loio, opens new tab. From a legal tech company, it transforms into a full-featured platform offering smart document drafting tools for everyone, from lawyers and business owners to individuals who seek reliable legal solutions. Loio is a powerful workspace where users can create, edit, complete, and sign documents without the need for additional software. 'It is a major step forward for our platform,' says Yehor Melnykov, CEO and co-founder of Loio. 'Our mission is to change people's perception of document workflow as something complicated and exhausting. With Loio tools, the whole process of document creation is intuitive and takes only a few minutes.' The updated Loio gives users access to a range of tools that enable them to work with documents of any complexity, anytime, and from any device. A growing collection of legal templates for any need — from personal to business — allows users to obtain professionally drafted contracts and forms without hiring a legal expert. Each of the available forms is created and reviewed by experienced lawyers, which grants more confidence and saves time. Lawyers spend 40-60% of their time, opens new tab drafting and reviewing contracts, whereas for a person without a legal background, creating even one document can take several days. Loio templates reduce this time considerably. For quick template completion, Loio offers a unique interview feature that guides users through the document by asking them simple questions. Based on the answers, the system automatically prepares a finished contract for further reviewing, signing, or downloading. With a newly launched PDF tool, users can either edit forms from Loio's 2,500+ pre-made templates or their own files. Adding and removing clauses, comments, initials, lists, and signatures takes a few clicks, and the insertion function allows one to complete documents with images and charts directly within the browser. Once the document is completed, users can instantly sign it online with a secure electronic signature system that follows U.S. laws, including the ESIGN Act, UETA, and ESRA. Loio also has an extensive library of legal guides that cover plenty of topics — from starting a business to what to include in a rental agreement. Written in plain language and regularly updated, these texts support users as they work through complex legal matters. Loio puts the right document drafting tools and information directly into the hands of those who need them, making the whole workflow easier, more comprehensible, and more secure. About Loio Loio is an all-in platform with a full set of tools for document creation, editing, and signing. It offers a collection of legal templates, a PDF editor, an e-sign, and comprehensive informational resources for people dealing with legal issues. The simplicity of use, accuracy, and data safety allow Loio to set a new standard for effective document workflow. For more information about the services, visit opens new tab. Media Contact Media Relationssupport@ ### SOURCE: Loio Copyright 2025 EZ Newswire See release on EZ Newswire
